• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Venus Concept Inc.

    6/11/25 4:05:18 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Venus Concept Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    92332W303

    (CUSIP Number)


    06/06/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92332W303


    1Names of Reporting Persons

    Orca Capital AG
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    GERMANY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    108,680.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    108,680.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    108,680.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 1,859,123 shares of Common Stock outstanding immediately after giving effect to the completion of the Issuer's registered offering as described in the Issuer's filings with the Securities and Exchange Commission, and excludes 217,360 shares of Common Stock issuable upon the exercise of warrants held by the Reporting Person, subject to the 4.99% blocker (defined below). Pursuant to the terms of the warrants as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2025, the Reporting Person cannot exercise any of the warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 4.99% of the Issuer's outstanding Common Stock (the "4.99% Blocker").


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Venus Concept Inc.
    (b)Address of issuer's principal executive offices:

    235 YORKLAND BLVD. SUITE 900 TORONTO A6 M2J4Y8
    Item 2. 
    (a)Name of person filing:

    Orca Capital AG
    (b)Address or principal business office or, if none, residence:

    Sperlring 2 85276 Hettenshausen Deutschland
    (c)Citizenship:

    Germany
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    92332W303
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    108,680
    (b)Percent of class:

    5.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    108,680

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    108,680

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Orca Capital AG
     
    Signature:/s/ Thomas Konig
    Name/Title:Thomas Konig/Director
    Date:06/11/2025
    Get the next $VERO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    Leadership Updates

    Live Leadership Updates

    See more
    • Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

      TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

      10/12/23 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

      TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

      10/11/22 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Ross J. Portaro as President of Global Sales

      TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

      10/12/21 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Madryn Asset Management, Lp

      4 - Venus Concept Inc. (0001409269) (Issuer)

      4/2/25 5:47:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Director Natale Anthony sold $13,194 worth of shares (42,768 units at $0.31) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      12/4/24 5:43:14 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Large owner Masters Michael Willingham sold $179,641 worth of shares (306,135 units at $0.59) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      10/2/24 7:54:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VERO
    Financials

    Live finance-specific insights

    See more
    • Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share. In a concurrent private placement, the Company issued unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that are immediately exercisable upon issuance and will expire eighteen months following the effective date of the registration statement cov

      6/9/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that will be immediately exercisable upon issuance and will expire eighteen months following the effective date of the regist

      6/6/25 11:35:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd ("Meta Healthcare Group") in an all-cash transaction valued at $20 million, subject to a customary working capital adjustment. The net proceeds from the transaction, once completed, will enhance the Company's balance sheet and financial condition and provide valuable capital to fund strategic growth initiatives. "We are pleased to announce one outcome of our evaluation of strategic alternatives to maximize shareholder value," sai

      6/6/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

      TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

      4/7/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2024 financial results will be released before the market opens on Monday, March 31, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on March 31, 2025 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13751985. A live webcast of the call will also be provided on the investor relations section of the

      3/3/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Third Quarter of Fiscal Year 2024 Financial Results on November 13, 2024

      TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, November 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13749236. A live webcast of the call will also be provided on the investor relations section of the Company's

      10/2/24 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Venus Concept Inc.

      DEFA14A - Venus Concept Inc. (0001409269) (Filer)

      6/12/25 4:19:19 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Venus Concept Inc.

      SCHEDULE 13G/A - Venus Concept Inc. (0001409269) (Subject)

      6/11/25 4:05:18 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      6/9/25 4:40:09 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/8/24 7:51:38 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/3/24 7:59:41 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

      SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

      9/30/24 9:53:26 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care